Tonix Pharmaceuticals Holding (TNXP) Operating Income: 2023-2025
Historic Operating Income for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$33.1 million.
- Tonix Pharmaceuticals Holding's Operating Income fell 112.59% to -$33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 29.43%. This contributed to the annual value of -$136.7 million for FY2024, which is 15.48% down from last year.
- As of Q3 2025, Tonix Pharmaceuticals Holding's Operating Income stood at -$33.1 million, which was down 16.86% from -$28.3 million recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's 5-year Operating Income high stood at -$15.6 million for Q3 2024, and its period low was -$77.3 million during Q2 2024.
- In the last 3 years, Tonix Pharmaceuticals Holding's Operating Income had a median value of -$27.3 million in 2023 and averaged -$30.0 million.
- Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's Operating Income was 63.40% (2025), while the steepest drop was 112.59% (2025).
- Over the past 3 years, Tonix Pharmaceuticals Holding's Operating Income (Quarterly) stood at -$27.3 million in 2023, then grew by 17.74% to -$22.5 million in 2024, then plummeted by 112.59% to -$33.1 million in 2025.
- Its last three reported values are -$33.1 million in Q3 2025, -$28.3 million for Q2 2025, and -$16.1 million during Q1 2025.